EGFR and neoplasm: In a high proportion (~30%) of non-small cell lung cancer (NSCLC) patients, the oncogenic driver of tumor growth is the constitutively activated epidermal growth factor receptor (EGFR, HER-1/ErbB1), a receptor tyrosine kinase of the ErbB family, which has been identified as an anticancer target [1].